In response to Wang Sicong's query, on the 16th, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) replied that Zhongxin Jingwei said that the company had never said "who recommended Lianhua to clear the plague" on any occasion. For the recent false public opinion information, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) had reported to the superior department.
On the 14th, Wang Sicong forwarded a video questioning whether the World Health Organization (hereinafter referred to as who) had recommended Lianhua Qingwen capsule. Affected by the "Wang Sicong storm", the share price fell by the limit on Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) 15, closing at 35.99 yuan / share.
has the WHO recommended Lianhua Qingwen
On the 14th, Wang Sicong forwarded a video produced by the blogger named "bedtime news editorial department". The video content mainly focused on whether Lianhua Qingwen capsule has been recommended by who to treat covid-19 pneumonia.
"Bedtime news editorial department" said that recently, several websites published articles under the titles of "who recognized the efficacy of traditional Chinese medicine in the treatment of covid-19, Lianhua Qingwen prevention and control obtained a reliable basis", "who recognized! Lianhua Qingwen contributed 'Chinese wisdom' to the global war", "traditional Chinese medicine showed great prestige in fighting the epidemic, who proved safe and effective, and recommended it to Member States".
"Bedtime news editorial department" believes that these articles link Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) and who meetings and promote Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) share price soaring.
So, first, does the who recommend Lianhua Qingwen capsule? Second, for the hot rumors on the Internet, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) is there any violation of letter approval? Third, who is profiting from it?
According to the "bedtime news editorial department", the source of these articles refers to the report of the expert evaluation meeting of the World Health Organization on the treatment of covid-19 pneumonia with traditional Chinese medicine (hereinafter referred to as the report) released on the official website of the World Health Organization on March 31.
However, the bedtime news editorial department said that the report only said that countries were encouraged to consider the treatment mode of integrated traditional Chinese and Western medicine explored by China. At the same time, this was only a suggestion, not to mention Lianhua Qingwen capsule.
According to the inquiry of China Singapore Jingwei, the WHO released the report of the expert evaluation meeting on the treatment of covid-19 pneumonia with traditional Chinese medicine on the official website on March 31, which was held from February 28 to March 2.
According to the report, the meeting evaluated 12 registered and published randomized controlled trials (RCTs) related to the role of traditional Chinese medicine in the treatment of covid-19.
According to the report, Dr. Yu Wenming, member of China's State Administration of traditional Chinese medicine, said at the meeting that the prevention and treatment of covid-19 by traditional Chinese medicine is an important factor for China to maintain a low disease course. Meanwhile, Dr. Yu Wenming said that during the epidemic period in Wuhan, the State Administration of traditional Chinese medicine, The administration of traditional Chinese medicine (China) has approved the sale of three kinds of traditional Chinese medicine through special approval procedures (Note: in the process of fighting the epidemic, the State Administration of traditional Chinese medicine has screened the effective prescriptions "three drugs and three prescriptions", "three drugs" are Jinhua Qinggan granules, Lianhua Qingwen granules and capsules, Xuebijing injection, and "three prescriptions" are Qingfei Paidu decoction, Huashi Baidu formula and Xuanfei Baidu formula), He also said that the State Food and Drug Administration will continue to optimize the diagnosis and treatment scheme of traditional Chinese medicine, screen the formula, evaluate the curative effect, analyze the effective formula and try to explain the curative effect mechanism scientifically.
The report also mentioned that the vice president of the Dongzhimen Hospital of Beijing University of Chinese Medicine, the director of the Department of internal medicine of the Beijing University of Chinese Medicine and the director of the Beijing Key Laboratory, and Shang Hong, deputy director of the Institute of cardiovascular diseases, were published in May 2020 in the "botanical medicine" Lianhua Qingwen capsule for the treatment of New Coronavirus pneumonia in a prospective, randomized, controlled, multicenter clinical study. The patients who took Lianhua Qingwen in the trial recovered their symptoms in a shorter time than those who did not receive the intervention of traditional Chinese medicine; The TCM clinical study of 2019 coronavirus disease shows that TCM Intervention shortens the remission period of covid-19 clinical symptoms.
The report points out that the main conclusions of the expert meeting include: first, the evidence evaluation report adopts an appropriate and rigorous method to determine the current level of clinical evidence and the safety of research TCM interventions used in the trial. The included trials involved different environments, different types of patients and outcome measurements from the results of the selected randomized controlled trial (RCT), the clinical trial value can be further verified to evaluate the potential benefits of the selected traditional Chinese medicine in the treatment of covid-19
Second, the expert group recognized the conclusion reached in the above clinical trials. For mild to moderate cases, compared with simple routine treatment, as an additional intervention measure of routine treatment, studied traditional Chinese medicine can shorten the virus clearance time, clinical symptom relief time and hospital stay
in addition, in the above-mentioned report, the World Health Organization recommended that Member States consider the possibility of using traditional Chinese medicine to treat covid-19 within their health care systems and regulatory frameworks
is the letter approval illegal
According to the "bedtime news editorial department", it questioned the rationality of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) share price soaring. Recently, several media issued documents linking Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) and who meetings. At the same time, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) share price soared. It rose continuously within the limit last week, so it had to issue an announcement of stock trading changes.
Zhongxin Jingwei noted that the articles on the above website were published from April 6 to April 8, but on March 31, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) raised the limit at 9:50, and then opened the limit at 13:24 on that day, the net inflow of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) main capital was 517 million yuan, accounting for 11.27%. This week, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) was abandoned by the main force, and the net outflow of individual shares was 2.106 billion yuan.
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) is there any speculation? On the 16th, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) responded to China Singapore Jingwei that first, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) has never said on any occasion that the WHO recommends Lianhua Qingwen; Second, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) has reported the recent false public opinion information to the superior department; Third, for the recent stock price fluctuation, the stock price fluctuation belongs to the market behavior, which has nothing to do with Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) and the company does not operate the stock price
Song Yixin, a lawyer of Shanghai hanlian law firm, analyzed Zhongxin Jingwei and said that false statements include false records, misleading statements, major omissions and improper disclosure of information.
in Song Yixin's opinion, if the world health organization does not recommend Lianhua Qingwen, even if the news is not sent by the company but from the market, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) it is necessary to correct the news in time "there is a possibility that someone is deliberately releasing information. In this regard, the CSRC should investigate and deal with it, including whether there are false statements, insider trading and stock price manipulation." Song Yixin said.
For the main capital flow problem, song Yixin analyzed that from the perspective of capital flow, if this flow is related to false information, listed companies should respond to false information in time. If it is suspected of information disclosure violations or stock price manipulation, the CSRC shall intervene in the investigation.
Huang Mengqi, a lawyer of Beijing Zhongwen (Shanghai) law firm, told Zhongxin Jingwei that for the news sent by the industry, it is impossible to directly judge which listed companies are malicious marketing. However, when there is false information, the listed company has the obligation of immediate clarification. In this case, if the listed company knows the information but does not clarify it, its behavior may constitute misleading information or false statement. If the information is disseminated by it, it will constitute a false statement, and the maker and related persons of the false statement shall bear corresponding responsibilities.
According to Article 60 of the Interim Regulations on the administration of stock issuance and trading, in case of a major event that may have a great impact on the market price of the shares of the listed company and is not known to the investors, the listed company shall immediately submit the report on the major event to the securities trading place and the CSRC, and publish it to the public to explain the essence of the event. However, if a listed company has sufficient reasons to believe that announcing the major event to the public will damage the interests of the listed company, and if it does not publish it, it will not lead to significant changes in the stock market price, it may not publish it with the consent of the securities exchange.
if a listed company is suspected of disclosing false information, what consequences will it face? "According to the provisions of the securities law, it is possible to warn, order correction, impose a fine and prohibit entry into the securities market. If the problem is serious, criminal responsibility can be investigated. If the securities fraud is established, investors whose rights and interests are damaged can file a civil compensation lawsuit." Song Yixin said .
